Literature DB >> 34779227

Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV.

Robert J Schieffer1, Ewa Bryndza Tfaily2, Richard D'Aquila3, George J Greene4, Alex Carballo-Diéguez5, Rebecca Giguere5, Christine Tagliaferri Rael5, Patrick F Kiser6, Thomas J Hope2.   

Abstract

Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptability, feasibility, and user experience with the device. In this study, n = 75 PrEP-prescribing physicians and n = 143 men having sex with men (MSM) at risk for HIV completed web-based surveys that directly compared the importance of eight to nine different implant features, respectively. Conjoint analysis determined the importance of these features, relative to each other. Implants presented in the study were well received, with a majority of physicians and MSM indicating that they were likely to recommend or use them. The implant was perceived as unique, reliable, and convenient, as well as able to deliver better compliance. The attributes most critical to the adoption of the implant among physicians and MSM were (1) the chance of becoming infected with HIV while on implant treatment, (2) the length of protection and size of the implant, and (3) the side effect advantages over current PrEP oral pill treatment. Some concerns about the implant included side effects and the product's safety (among MSM) and the cost or insurance coverage level for the implant (both physicians and MSM). There was also some resistance to the implantation procedure itself.

Entities:  

Keywords:  HIV prevention; MSM; PrEP; conjoint analysis

Mesh:

Substances:

Year:  2021        PMID: 34779227      PMCID: PMC9048179          DOI: 10.1089/AID.2021.0075

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.

Authors:  George J Greene; Greg Swann; Angela J Fought; Alex Carballo-Diéguez; Thomas J Hope; Patrick F Kiser; Brian Mustanski; Richard T D'Aquila
Journal:  AIDS Behav       Date:  2017-05

2.  Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city.

Authors:  Katherine H A Footer; Sahnah Lim; Christine Tagliaferri Rael; George J Greene; Alex Carballa-Diéguez; Rebecca Giguere; Michelle Martinez; Walter Bockting; Richard D'Aquila; Susan G Sherman
Journal:  AIDS Care       Date:  2019-03-01

3.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Authors:  Jean-Michel Molina; Isabelle Charreau; Bruno Spire; Laurent Cotte; Julie Chas; Catherine Capitant; Cecile Tremblay; Daniela Rojas-Castro; Eric Cua; Armelle Pasquet; Camille Bernaud; Claire Pintado; Constance Delaugerre; Luis Sagaon-Teyssier; Soizic Le Mestre; Christian Chidiac; Gilles Pialoux; Diane Ponscarme; Julien Fonsart; David Thompson; Mark A Wainberg; Veronique Doré; Laurence Meyer
Journal:  Lancet HIV       Date:  2017-07-23       Impact factor: 12.767

Review 4.  The promise and pitfalls of long-acting injectable agents for HIV prevention.

Authors:  Raphael J Landovitz; Ryan Kofron; Marybeth McCauley
Journal:  Curr Opin HIV AIDS       Date:  2016-01       Impact factor: 4.283

5.  Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).

Authors:  Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J Greene; Susan G Sherman; Katherine H A Footer; Richard T D'Aquila; Alex Carballo-Diéguez; Thomas J Hope
Journal:  AIDS Behav       Date:  2020-05

6.  Qualitative Consumer Research on Acceptance of Long-Acting Pre-Exposure Prophylaxis Products Among Men Having Sex with Men and Medical Practitioners in the United States.

Authors:  Bobby J Calder; Robert J Schieffer; Ewa Bryndza Tfaily; Richard D'Aquila; George J Greene; Alex Carballo-Diéguez; Rebecca Giguere; Patrick F Kiser; Thomas J Hope
Journal:  AIDS Res Hum Retroviruses       Date:  2018-10       Impact factor: 2.205

7.  Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.

Authors:  Jared M Baeten; Thesla Palanee-Phillips; Nyaradzo M Mgodi; Ashley J Mayo; Daniel W Szydlo; Gita Ramjee; Brenda Gati Mirembe; Felix Mhlanga; Portia Hunidzarira; Leila E Mansoor; Samantha Siva; Vaneshree Govender; Bonus Makanani; Logashvari Naidoo; Nishanta Singh; Gonasagrie Nair; Lameck Chinula; Urvi M Parikh; John W Mellors; Iván C Balán; Kenneth Ngure; Ariane van der Straten; Rachel Scheckter; Morgan Garcia; Melissa Peda; Karen Patterson; Edward Livant; Katherine Bunge; Devika Singh; Cindy Jacobson; Yuqing Jiao; Craig W Hendrix; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Kristine Torjesen; Annalene Nel; Zeda Rosenberg; Lydia E Soto-Torres; Sharon L Hillier; Elizabeth R Brown
Journal:  Lancet HIV       Date:  2021-02       Impact factor: 12.767

8.  Long-acting implants to treat and prevent HIV infection.

Authors:  Ethel D Weld; Charles Flexner
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

9.  A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence?

Authors:  David Sidebottom; Anna Mia Ekström; Susanne Strömdahl
Journal:  BMC Infect Dis       Date:  2018-11-16       Impact factor: 3.090

Review 10.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.

Authors:  Virginia A Fonner; Sarah L Dalglish; Caitlin E Kennedy; Rachel Baggaley; Kevin R O'Reilly; Florence M Koechlin; Michelle Rodolph; Ioannis Hodges-Mameletzis; Robert M Grant
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.